HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.

AbstractBACKGROUND:
The objective of this study was to assess activity and toxicity in patients with newly diagnosed, advanced-stage epithelial ovarian cancer (EOC) who were receiving dose-intense paclitaxel, cyclophosphamide, cisplatin, and filgrastim delivered with a flexible dosing schedule.
METHODS:
Patients with stage III/IV EOC received cyclophosphamide 750 mg/m(2), followed by a 24-hour infusion of paclitaxel 250 mg/m(2) and cisplatin 75 mg/m(2) on Day 2. Filgrastim began on Day 3 at 10 microg/kg daily for 9 days. Patients received 6 cycles of all drugs. Those who achieved a pathologic complete response or had microscopic residual disease at the conclusion of 6 cycles of therapy received an additional 2 to 4 cycles of paclitaxel with cyclophosphamide. Patients who had an objective response continued on cyclophosphamide and paclitaxel.
RESULTS:
Sixty-two patients were enrolled. Thirty-two of 62 patients had stage IIIC disease, and 26 of 62 patients had stage IV disease. According to an intent-to-treat analysis, 55 patients (89%) experienced a clinical complete remission. At a median potential follow-up of 11.4 years, the median progression-free survival was 18.9 months, and the median survival was 5.4 years. The most serious toxicity was grade 3/4 neutropenic fever (35%). Although all participants developed peripheral neuropathy, improvement in neuropathic symptoms began with the decrease or cessation of paclitaxel.
CONCLUSIONS:
The studied regimen yielded a high response rate and encouraging overall survival. The current data and those reported by the Japanese Gynecologic Oncology Group suggest that further study is warranted of dose-dense or dose-intense paclitaxel regimens in women with newly diagnosed, advanced-stage EOC.
AuthorsGisele A Sarosy, Mahrukh M Hussain, Michael V Seiden, Arlan F Fuller, Najmosama Nikrui, Annekathryn Goodman, Lori Minasian, Eddie Reed, Seth M Steinberg, Elise C Kohn
JournalCancer (Cancer) Vol. 116 Issue 6 Pg. 1476-84 (Mar 15 2010) ISSN: 0008-543X [Print] United States
PMID20091841 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Intramural)
Chemical References
  • Cyclophosphamide
  • Paclitaxel
  • Cisplatin
Topics
  • Adenocarcinoma (drug therapy, mortality, pathology)
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Cisplatin (administration & dosage)
  • Cyclophosphamide (administration & dosage)
  • Drug Administration Schedule
  • Female
  • Humans
  • Middle Aged
  • Ovarian Neoplasms (drug therapy, pathology)
  • Paclitaxel (administration & dosage)
  • Prognosis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: